Joshua Brumm
2021 - Dyne Therapeutics
In 2021, Joshua Brumm earned a total compensation of $4.1M as President and Chief Executive Officer at Dyne Therapeutics, a 66% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $451,830 |
|---|---|
| Option Awards | $1,509,121 |
| Salary | $562,000 |
| Stock Awards | $1,550,653 |
| Other | $13,007 |
| Total | $4,086,611 |
Brumm received $1.6M in stock awards, accounting for 38% of the total pay in 2021.
Brumm also received $451.8K in non-equity incentive plan, $1.5M in option awards, $562K in salary and $13K in other compensation.
Rankings
In 2021, Joshua Brumm's compensation ranked 3,276th out of 12,406 executives tracked by ExecPay. In other words, Brumm earned more than 73.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,276 out of 12,406 | 74th |
Division Manufacturing | 1,328 out of 5,492 | 76th |
Major group Chemicals And Allied Products | 539 out of 2,368 | 77th |
Industry group Drugs | 479 out of 2,089 | 77th |
Industry Pharmaceutical Preparations | 332 out of 1,536 | 78th |
Source: SEC filing on April 22, 2022.
Brumm's colleagues
We found two more compensation records of executives who worked with Joshua Brumm at Dyne Therapeutics in 2021.
News
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021
Kaleido Biosciences CEO Alison Lawton's 2019 pay falls 57% to $2.9M
May 8, 2020